Last reviewed · How we verify
thiazolidinediones
thiazolidinediones is a Small molecule drug developed by Sanofi. It is currently FDA-approved. Also known as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone.
Thiazolidinediones are a class of small molecule heterocyclic compounds used in the treatment of type 2 diabetes mellitus. They are FDA-approved drugs, with pioglitazone being one of the two approved medications in this class.
At a glance
| Generic name | thiazolidinediones |
|---|---|
| Also known as | oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (PHASE1, PHASE2)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thiazolidinediones CI brief — competitive landscape report
- thiazolidinediones updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about thiazolidinediones
What is thiazolidinediones?
Who makes thiazolidinediones?
Is thiazolidinediones also known as anything else?
What development phase is thiazolidinediones in?
Related
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing